Cancer name Ovarian Cancer
Cancer Type OV
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment 5-azacytidine (AZA)
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Cell
Signature CD4+ T cells
Official Symbol CD4+ T cell
Mode of action CE_D_UP
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description In support of the fact that in vivo epigenetic treatment altershost immune cell populations in the tumor microenvironment,we find that AZA treatment increases expression of viral defensegenes in CD8+ and CD4+ T cells and in CD11b+ myeloid cells in the ascites fluid of treated, tumor-bearing mice.
PMID 29203668
Title Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden